Oncology Treatment Innovations 2026: The Therapies Reshaping Cancer Care

1. CAR-T Cell Therapy: Moving Beyond Haematology

Chimeric antigen receptor T-cell (CAR-T) therapy is no longer a niche haematological treatment — it is becoming a foundational pillar of modern oncology. The mechanism is elegant: a patient's own T-cells are extracted, genetically re-engineered to express a synthetic receptor (the CAR) that recognises a specific antigen on cancer cells, expanded in the laboratory, and reinfused. Once back in the body, they seek and destroy antigen-expressing cells with an immune precision that conventional chemotherapy cannot match.

The approved indication landscape has expanded rapidly. As of mid-2026, FDA-approved CAR-T products target CD19, BCMA, and CD22 across indications including relapsed/refractory large B-cell lymphoma, acute lymphoblastic leukaemia, follicular lymphoma, and multiple myeloma. Response rates in multiply relapsed patients — patients who have exhausted standard options — frequently exceed 50%, a figure that was inconceivable a decade ago in these settings.

What's New in 2026: Solid Tumours and Allogeneic Formats

The frontier has shifted. Several high-priority challenges are now close to resolution. First, solid tumour CAR-T has matured from proof-of-concept to active late-phase trials. Glioblastoma (targeting EGFRvIII and IL13Ra2), HER2-positive breast and gastric cancers, mesothelioma (targeting mesothelin), and EGFR-positive non-small cell lung cancer are all under active investigation with early signals of activity in the Phase I–II range.

Second, allogeneic ("off-the-shelf") CAR-T — using donor T-cells rather than the patient's own — is moving toward scalability. The bottleneck with autologous therapy has always been manufacturing: each patient requires weeks and significant cost. Allogeneic formats, including those using iPSC-derived T-cells, promise faster access and consistent product quality, though immunogenic and persistence challenges remain under active investigation.

For patients with relapsed or refractory haematological cancers, CAR-T eligibility screening now begins earlier in the treatment pathway than it did even two years ago. Discuss it with your oncologist before exhausting standard options, since bridging therapy and manufacturing timing both matter.

2. Antibody-Drug Conjugates: The Precision Payload Revolution

Antibody-drug conjugates (ADCs) are arguably the most commercially and clinically productive drug class in oncology right now. The concept is deceptively straightforward: take a monoclonal antibody that binds to a cancer-associated antigen, chemically attach a potent cytotoxic payload via a stable linker, and you have a targeted missile that delivers chemotherapy only where it is needed.

Early ADC development was limited by linker instability (premature payload release in circulation) and suboptimal payloads. Third-generation ADCs have solved both problems. Drugs like trastuzumab deruxtecan (Enhertu) use cleavable linkers that release payload selectively inside tumour cells, and next-generation topoisomerase I inhibitor payloads that generate a "bystander effect" — killing adjacent antigen-negative cells via diffusion. This fundamentally changes the risk calculus for tumours with heterogeneous antigen expression.

The implication for oncologists is significant: ADC therapy is now appropriate in heavily pre-treated patients and, increasingly, in earlier lines. HER2-low breast cancer — previously considered HER2-negative for therapeutic purposes — is now a treatable biomarker category because of trastuzumab deruxtecan's efficacy across the HER2 expression spectrum.

3. Bispecific Antibodies: Redirecting the Immune System

Bispecific antibodies (BsAbs) are engineered proteins that bind two different targets simultaneously. In oncology, the dominant format binds a tumour antigen on one arm and a T-cell surface molecule (most commonly CD3, the T-cell receptor complex) on the other. The effect is to physically bridge a T-cell to a tumour cell, forcing an immune synapse and triggering T-cell-mediated killing — without requiring the patient's immune system to have pre-existing tumour-specific T-cell clones. This is fundamentally different from checkpoint inhibitors, which amplify existing responses.

The clinical validation came first in haematology. Blinatumomab, the CD19xCD3 bispecific approved for ALL, demonstrated complete remission rates of around 40% in patients who had already failed standard therapy. The multiple myeloma setting has since seen a wave of BCMA-targeting bispecifics (teclistamab, elranatamab) and CD38-targeting formats, with response rates in the 60–70% range in patients with quad-refractory disease.

"Bispecific antibodies represent the most accessible form of T-cell redirection therapy — no manufacturing delay, no pre-conditioning requirement in all settings, and scalable off-the-shelf supply. Their expansion into solid tumours is one of the most watched developments in 2026 oncology."

Solid tumour bispecifics face the antigen-density and immunosuppressive microenvironment challenges familiar from CAR-T, but novel combinations with checkpoint inhibitors and tumour microenvironment modulators are showing early promise. From a clinical trial design perspective, bispecifics present interesting response assessment questions — cytokine release syndrome monitoring and unique adverse event profiles require protocol-level planning.

4. PROTAC Targeted Protein Degraders: A New Mechanism Class

PROTACs — Proteolysis-Targeting Chimeras — represent perhaps the most conceptually radical innovation class in 2026 oncology. Rather than inhibiting a protein's function by occupying its active site (the mechanism underlying all classical small-molecule drugs), a PROTAC eliminates the protein entirely. It does this by acting as a molecular glue: one end binds the target protein, the other binds an E3 ubiquitin ligase enzyme. The proximity causes the target to be polyubiquitinated and flagged for destruction by the cell's own proteasome — the cellular "waste disposal" system.

Why does this matter clinically? Because many of the most important cancer-driving proteins are transcription factors, scaffold proteins, and intrinsically disordered proteins — molecules with no well-defined enzymatic active site to block. These have long been called "undruggable." PROTACs bypass the need for an active site entirely: they only need to bind the surface of the protein, making previously untargetable proteins accessible for the first time.

Pipeline Status in 2026

The PROTAC pipeline in oncology has moved from academic proof-of-concept to credible Phase II data. Key targets under active clinical investigation include:

• AR (androgen receptor) — ARV-110 in metastatic castration-resistant prostate cancer; Phase II data show activity in AR-mutant tumours that are resistant to enzalutamide and abiraterone
• BCL-2/BCL-xL — degraders targeting the anti-apoptotic proteins central to lymphoma and CLL survival
• BRD4 and BET bromodomains — transcriptional co-activators amplified in multiple cancer types
• KRAS G12C — second-generation approaches combining covalent KRAS inhibition with degradation to overcome acquired resistance

The field is moving fast. For clinical investigators and sponsors, PROTAC trials introduce novel PK/PD endpoints — protein degradation levels, hook-effect monitoring, and degrader concentration optimisation — that require sophisticated biomarker integration into protocol design.

5. Radioligand Therapy: Targeted Radiation at the Molecular Level

Radioligand therapy (RLT) — also called targeted radionuclide therapy — delivers a therapeutic radioactive isotope directly to cancer cells using a tumour-targeting molecule. The concept exists at the intersection of nuclear medicine and precision oncology: the "ligand" (a small molecule, peptide, or antibody fragment) homes to a receptor overexpressed on cancer cells; the attached radioisotope then destroys the cell and its immediate neighbours through local radiation, while sparing distant healthy tissue.

The field reached a major inflection point with the Phase III VISION trial, which demonstrated a statistically significant and clinically meaningful overall survival benefit for [177Lu]Lu-PSMA-617 (lutetium PSMA, brand name Pluvicto) in metastatic castration-resistant prostate cancer. The FDA approved it in 2022, and it has since become a standard-of-care option for PSMA-positive patients who have progressed on hormonal therapy and taxane chemotherapy.

Expansion Beyond Prostate Cancer

The VISION data catalysed investment across tumour types. Active 2026 clinical programmes include RLT targeting:

• Somatostatin receptors (SSTR2) in neuroendocrine tumours — building on the established peptide receptor radionuclide therapy (PRRT) framework
• FAP (fibroblast activation protein) in breast, colorectal, and pancreatic cancers — FAP is expressed on cancer-associated fibroblasts across many solid tumours
• CD38 and PSMA analogues in haematological malignancies
• HER2-targeting radioligands in HER2-amplified gastric and breast cancers

Actinium-225 (Ac-225) based RLT is attracting particular attention. Unlike Lutetium-177, which emits beta particles, Ac-225 emits alpha particles — higher-energy, shorter-range radiation with significantly higher cell-killing efficiency per decay. Early Phase I data in prostate cancer, even in patients who have progressed on lutetium PSMA, show activity in this ultra-refractory setting.

6. Tumour-Infiltrating Lymphocyte Therapy: The Solid Tumour Cell Therapy

Tumour-infiltrating lymphocyte (TIL) therapy is cell therapy designed specifically for solid tumours — filling a gap that CAR-T has not yet bridged. The process begins with a surgical resection of a tumour fragment. The naturally occurring T-cells that have already infiltrated the tumour (and thus already recognise tumour antigens) are extracted, massively expanded in the laboratory, and reinfused following lymphodepletion. Unlike CAR-T, no genetic engineering is required — TIL therapy uses the patient's native polyclonal immune response.

The first FDA approval of a TIL therapy came in 2024: lifileucel (Amtagvi) for unresectable or metastatic melanoma in patients who have progressed on a PD-1 inhibitor and (if BRAF V600-mutant) a BRAF inhibitor. The C-144-01 trial showed an objective response rate of around 31% in this highly treatment-refractory population — in melanoma, a tumour type that has already undergone an immunotherapy revolution, a 31% ORR in progression-after-checkpoint patients is clinically meaningful.

Active investigation in 2026 is extending TIL therapy into cervical cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, and colorectal cancer. The operational complexity is significant — surgical harvest, multi-week manufacturing, lymphodepletion, and ICU-level monitoring for cytokine release — which makes site selection and CRO capability critical factors in trial viability.

7. What These Innovations Mean for Clinical Trial Design

The wave of mechanistically novel oncology agents has fundamentally changed how clinical trials need to be designed, operated, and analysed. Several implications are worth noting for sponsors, investigators, and site networks:

Biomarker-driven eligibility is no longer optional. Trials evaluating CAR-T, ADCs, bispecifics, and RLT all require pre-screening for expression of the target antigen. The operational burden of central testing at scale, with turnaround times that match patient accrual timelines, is now a site capability question — not just a laboratory question.

Novel endpoints require pre-specification. Response criteria developed for cytotoxic agents (RECIST 1.1) do not always apply cleanly to cell therapies or radioligand treatments. Pseudo-progression, inflammatory flares, and delayed responses require pre-specified sensitivity analyses and alternative endpoint hierarchies. Post-hoc adjustment is not an option under FDA scrutiny.

Adverse event monitoring demands protocol-level infrastructure. CAR-T, bispecific antibodies, and TIL therapy all carry risk of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS). Sites need trained staff, on-call protocols, and access to tocilizumab as a condition of trial activation.

Adaptive design adds value in this setting. With multiple targets, multiple biomarker-defined populations, and rapidly evolving standard-of-care landscapes, platform and adaptive trial designs allow sponsors to maximise information from every patient enrolled. The regulatory science for adaptive oncology trials is now sufficiently mature to integrate into Phase II/III programs without excessive approval risk.

KCLG Medical operates an oncology-focused clinical research site at Oak Brook, IL, equipped for Phase I–II trial delivery including biospecimen processing, cold chain, and protocol-level safety monitoring. Sponsors evaluating US site networks for the innovation classes described above can download our capability statement or contact the team directly.

Frequently Asked Questions